

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B8

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, C12N 15/12, 15/86	A1	(11) International Publication Number: WO 97/48419
		(43) International Publication Date: 24 December 1997 (24.12.97)

(21) International Application Number: PCT/US97/12131

(22) International Filing Date: 20 June 1997 (20.06.97)

(30) Priority Data:

60/020,812	20 June 1996 (20.06.96)	US
9615787.0	26 July 1996 (26.07.96)	GB

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MORSY, Manal, A. [EG/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GU, Ming, Cheng [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). ZHAO, Jing [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). CASKEY, C., Thomas [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: GENE THERAPY FOR OBESITY

(57) Abstract

Gene therapy can treat obesity in mammals. An obesity regulating gene is delivered to a mammal. Preferably, the gene encodes leptin or a leptin receptor. The protein which is delivered and expressed *in vivo* is more effective than protein which is injected into the animal.

28

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE OF THE INVENTION
GENE THERAPY FOR OBESITY

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not Applicable

STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not Applicable

10 REFERENCE TO MICROFICHE APPENDIX
Not Applicable

FIELD OF THE INVENTION

15 This invention relates to methods of gene therapy for obesity. This invention also relates to vectors useful in this gene therapy.

BACKGROUND OF THE INVENTION

20 Leptin is a protein expressed by the *ob* gene. Leptin is secreted by adipose tissue and appears to be both a satiety factor and a regulator of metabolism (Levin *et al.*, 1996 *Proc. Natl Acad. Sci. USA* 93:1726-1730). Both the mouse gene and its human homologue have recently been identified and sequenced (Zhang *et al.*, 1994 *Nature (London)* 372:425-431.)

25 Mice which are homozygous for the *ob* gene (*ob/ob*) are obese, perhaps due to an underexpression of leptin. When *ob/ob* mice are given daily injections of recombinant protein, their food intake was markedly inhibited and they experienced a reduction in body weight and fat. In lean (i.e. wild-type) mice, daily injections of leptin lead to
30 modest decreases of food intake and body weight. The results for body fat have been contradictory. (Pelleymounter *et al.*, 1995, *Science* 269:540-543; Halaas *et al.*, 1995 *Science* 269: 543-546; and Campfield *et al.*, 1995 *Science* 269:546-549.

35

Obesity in humans is a major disorder associated with mortality, and may result from a number of causes, and at least some may be due to an insufficient amount of leptin produced. Since leptin is a protein, and vulnerable to breakdown and inactivation by the gastrointestinal system,
5 it cannot be delivered orally. It would be desirable to develop a therapy for leptin delivery for obese patients whose obesity is due, in part to a paucity of leptin.

Some forms of obesity do not appear to be treatable by the administration of leptin. In these cases, it is possible that the problem
10 may be due to an insufficient amount of leptin receptors on the cell surface. Alternatively, the receptors which are present on the cell surface may contain mutations which do not allow them to bind to leptin efficiently or efficiently process the signal generated by the leptin binding. Currently no therapy exists which could augment or replace
15 these receptors.

SUMMARY OF THE INVENTION

Not Applicable

20 BRIEF DESCRIPTION OF THE INVENTION

This invention is related to gene therapy for obesity. One aspect of this invention involves a method of treating obesity, lowering serum glucose levels or lowering serum insulin levels in a mammal in need of such therapy comprising delivering a gene encoding an obesity
25 regulating gene to said mammal; and allowing sufficient time to pass for transcription and translation of the obesity regulating gene.

Some types of obesity are caused by an insufficient amount of leptin or an insufficient amount of functional leptin receptors present on the cell surface. Thus, another aspect of this invention is a method of
30 treating obesity comprising delivering a gene encoding leptin or a leptin receptor to a mammal; and allowing sufficient time to pass for transcription and translation of the leptin or leptin receptor gene.

A specific embodiment of this invention is gene therapy for a mammal whose obesity, elevated level of serum glucose or elevated level of insulin is due, at least in part to an insufficient amount of leptin produced. By "insufficient amount of leptin produced" it is envisioned that the animal may produce functional leptin, but at lower levels than required; a complete inability to produce leptin; or production of a mutated form of leptin which either functions less efficiently than native leptin or does not function at all. Thus, this invention is directed to a method of treating obesity, an elevated level of serum glucose or an elevated insulin, which is, at least in part, due to an insufficient amount of leptin produced by a mammal comprising: delivering a gene encoding leptin to the mammal and allowing sufficient time to pass for transcription and translation of the leptin gene.

Obesity may occur in an animal which is producing normal quantities of leptin, but whose leptin receptors are either not able to bind and process the leptin properly, or have not been produced in sufficient quantity. These situations may be remedied by gene therapy using a leptin receptor. Thus another aspect of this invention is a treatment for obesity, excess plasma insulin levels or excess plasma glucose levels, any of which are a result, at least in part, of an insufficient amount of functional leptin receptor production by a mammal. Thus, one aspect of this invention is a method of increasing the amount of leptin receptors in a mammal comprising: delivering a gene encoding a leptin receptor to the mammal, and allowing sufficient time to pass for transcription and translation of the leptin receptor gene.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a photograph of two *ob/ob* mice. The mouse on the right is from a control group. The mouse on the left received gene therapy in accordance with this invention.

Figure 2 is a graph showing the body weight changes of mice treated with recombinant human leptin protein. Injections of human recombinant leptin were given daily IP, at 1 μ g/gm body weight. Arrows indicate bleeding points.

Figure 3 is a graph showing body weight changes of mice treated with adenovirus carrying a reporter gene (β -galactosidase), used as a control.

Figure 4 is a graph showing body weight changes of mice treated with adenovirus carrying the human leptin gene.

Figure 5 is a graph showing the percent of body weight changes for all groups of mice.

Figure 6A (left graph) is a graph showing the amount of human leptin found in the plasma of mice treated with adenovirus containing the leptin gene. Figure 6B (right graph) shows results for mice treated with five daily injections of recombinant human leptin.

Figure 7A (left graph) shows the amount of insulin and leptin in plasma of mice treated with adenovirus containing the leptin gene. Figure 7B (right graph) shows the amount of insulin and leptin in plasma of mice treated with recombinant human leptin injections.

Figure 8 shows glucose levels of the mice treated with either recombinant leptin, reporter gene or adenovirus containing the leptin gene.

As used throughout the specification and claims, the following definitions apply:

"Native" a gene or protein is native if it naturally occurs in a given organism.

"Leptin gene": a gene from any mammal which encodes a native leptin, or a derivative thereof. A "derivative" is a modified leptin molecule which retains at least 80% of the biological activity of native leptin.

"Leptin receptor": a gene from any mammal which encodes a native leptin receptor, or a derivative thereof. A "derivative" is a modified receptor molecule which binds native leptin at least 80% as efficiently as a native receptor molecule.

"Obesity regulating gene": a gene whose gene product is involved in the regulation of obesity in a mammal, including genes encoding leptin, leptin receptors, neuropeptide Y, and the like.

In the past, recombinant leptin has been administered to animals who exhibiting an obese phenotype, and a daily injection has been shown to decrease body weight. There are numerous
5 disadvantages to this method of treating obesity, however. First, this method is helpful only for those animals whose obesity is caused, at least in part by an insufficient amount of leptin produced. Not all obesity is due to this defect. Further, injections are not a particularly convenient method of treatment, particularly for long-term treatments. In addition,
10 the half-life of leptin is short, so the duration of the treatment was found to be only about 24 hours, after which the animals were observed to regain weight.

This invention solves the problems associated with a daily administration of recombinant protein by providing a vector which can
15 express leptin or a leptin receptor *in vivo*. It has been surprisingly found that leptin which is expressed *in vivo* is more advantageous than administration of recombinant leptin; its effects last longer, and most surprisingly, is up to 20 fold more potent than recombinant leptin administered by injection.

20 Expression of a leptin receptor or neuropeptide Y *in vivo* allows for treatment of heretofore untreatable types of obesity.

Genes

The sequences of leptin and leptin genes from various
25 species are known (Zhang *et al.*, 1994 *Nature* 372:425; Ogawa *et al.*, 1995 *J. Clin. Invest.* 96:1647-1652; Murakami *et al.*, 1995 *Biochem. Biophys. Res. Commun.* 209:944; and Considine *et al.*, 1995
J. Clin. Invest. 95:2986; each of which is hereby incorporated by reference). If desired, genes encoding leptin derivatives may also be
30 used. Since the amino acid and nucleotide sequence of leptin is known, it is well within the skill of one of the ordinary artisan to construct a nucleotide sequence which encodes a desired mutant form of leptin. These can be used to study structure and function relationships involved in leptin binding and signaling in the transgenic animal model.

The amino acid sequences of leptin receptors and the nucleic acid sequences of genes encoding leptin receptors are also known; see, for example Toriaglla *et al.*, 1995, *Cell* 83:1-20 which is hereby incorporated by reference. The leptin receptors can exist in various isoforms, due to alternate splicing. The biological consequences of the presence of many of these isoforms is not clearly understood. However, a mutation that results in premature termination of the long form of the mouse leptin receptor is apparently responsible for the obese phenotype of the *db/db* mouse (Lee *et al.*, 1996, *Nature* 379:632-635; Chua *et al.*, 1996, *Science* 271:994-996; and Chen *et al.*, 1996, *Cell* 84:491-495).

In further aspects of this invention, a derivative leptin receptor is introduced into a mammal, and the resulting mammal can be used to study structure and functional relationships between leptin binding and the leptin receptor.

The gene which encodes the leptin or leptin receptor should also contain at least one element which allows for expression of the gene when introduced into the host cell environment. These sequences include, but are not limited to promoters, response elements, and enhancer elements. In a preferred aspect of this invention, promoters are chosen which are regulatable; i.e. are inducible rather than constitutive. Particular examples of such promoters include: Sr-alpha, CMV, regulatable tet, P-450, albumin and the like.

25 Vector

The heterologous leptin or leptin receptor gene may be delivered to the organism using a vector or other delivery vehicle. DNA delivery vehicles can include viral vectors such as adenoviruses, adeno-associated viruses, and retroviral vectors. See, for example: Chu et al. 1994 *Gene Ther* 1: 292-299; Couture et al. 1994 *Hum Gene Ther* 5:667-677; and Eiverhand et al. 1995 *Gene Ther* 2: 336-343. Non-viral vectors which are also suitable include DNA-lipid complexes, for example liposome-mediated or ligand/ poly-L-Lysine conjugates, such as asialoglyco-protein-mediated delivery systems. See, for example:

Felgner et al. 1994 *J. Biol. Chem.*, 269: 2550-2561; Derossi et al. 1995, *Restor. Neurol. Neuros.* 8: 7-10; and Abcallah et al. 1995 *Biol. Cell* 85: 1-7.

5 If a vector is chosen as the delivery vehicle for the obesity
regulating gene, it may be any vector which allows expression of the
gene in the host cells. It is preferable if the vector also is one which is
capable of integrating into the host genome, so that the gene can be
expressed permanently, but this is not required. In cases where the
vector does not integrate into the host genome, the expression of the
10 gene may be transient rather than permanent.

One vector which is suitable for transient expression of the
ob gene is an adenovirus which has a deletion in the E1 gene. Such
vectors are known, as taught in the aforementioned WO 95/00655 and
Mitani *et al.*, 1995 publications. These viruses preferentially infect
15 hepatocytes, where they persist for approximately 3-4 weeks after the
initial infection. While in the hepatocytes, these viruses can express the
heterologous gene.

The vector is administered to the host, generally by IV
injection. Suitable titers will depend on a number of factors, such as the
20 particular vector chosen, the host, strength of promoter used and the
severity of the disease being treated. For mice, an adenovirus vector is
preferably administered as an injection at a dose range of from about
 5.0×10^6 to about 10×10^6 plaque forming units (PFU) per gram body
weight. Preferred dosages range from at least about $6-9 \times 10^6$ PFU/gm
25 body weight, and more preferred is from at least about $6.7-8.6 \times 10^6$
PFU/gm body weight (equivalent to approximately at least $1-5 \times 10^8$
PFU for mice).

Thus this invention specifically is directed to a method of
treating obesity, elevated serum glucose levels or elevated insulin levels
30 which is, at least in part, due to an insufficient amount of leptin or leptin
receptors by a mammal comprising:

- a) transfecting the mammal with a viral vector
comprising a gene encoding leptin or leptin
receptors; wherein said vector further comprises at

least one element regulating its expression in a mammalian tissue; and

- b) allowing sufficient time to pass for transcription and translation of the leptin gene.

5

Hosts

Animals which transiently express the *ob* or *ob*-receptor gene products are valuable research tools. For example, they can be used to monitor the effects of decreasing amounts of leptin, or the effect of various exogenously supplied substances (such as hormones or putative leptin receptor agonists and antagonists) in an environment of decreasing leptin availability.

Aside from making animal models useful in studying various aspects of obesity, this invention is specifically directed to gene therapy for humans.

15

In accordance with this invention, mice which are obese (*ob/ob*) have been injected with an adenovirus containing the human leptin gene, although the leptin gene from any desired species may be used, and in preferred embodiments, the gene which is from the same species as the host is used. These were compared with *ob/ob* mice injected with an adenovirus containing only a marker gene (β -galactosidase), those receiving injections of recombinant leptin, and to untreated controls. Further controls used in some of the experiments are *dh/dh* mice (obese, but unresponsive to leptin injections).

20

25

Body-weight: Figure 2 illustrates the body weight changes for mice receiving 1 μ g/gm body weight human recombinant leptin protein injections daily, compared to untreated controls. Animals receiving leptin were injected for five consecutive days, shown by the darkened symbols on the graph. All the animals receiving the leptin lost weight within 24 hours post-injection. All animals gain weight within 48 hours after the last IP injection. Figure 3 illustrates the weight measured for mice receiving various titers of an adenovirus carrying

30

the reporter gene. All animals continued to gain weight post injection. Figure 4 shows the results for mice receiving an adenovirus carrying the leptin gene. As can be seen from the graph, all animals lost weight within 24 hours post injection. They continued to loose weight for 1-2 weeks post treatment. The injections were effective over a relatively large titer range, and a dose-effect was noted.

Along with absolute changes in weight, the percentage body weight change was calculated for all groups. In the animals treated with recombinant leptin injections, weight loss plateaued at day three, and from day 1-5 post treatment, a 4.7% loss in body weight was noted. In those mice treated with the vector carrying the leptin gene, weight loss persisted over a 10-12 day period, and resulted in an 18.61% loss in body weight. Furthermore, over days 1-5 post treatment, a 9.17% loss in body weight was observed compared to only 4.7% loss in the recombinant leptin treated mice. This is illustrated in Figure 5.

Leptin: The amount of human leptin in plasma was measured in the animals which received injections of human recombinant leptin and those which received the vector carrying the leptin gene. Those receiving the recombinant protein were noted to have leptin levels which were approximately 20-fold higher than the amount of leptin found in control (lean, wild type) animals; peak amounts of 399.8 ± 40.91 ng/ml. Those receiving the leptin gene had levels of leptin in their plasma which was within the normal range found in a wild-type mouse (17.52 ± 4.66 ng/ml). In both groups of animals, weight gain was synchronized with the fall of human leptin detected in the plasma. This is illustrated in Figure 6.

Insulin: The amount of insulin in the plasma was measured in both the animals receiving recombinant protein and those which received the gene therapy. This is illustrated in Figure 7. In both groups, insulin levels were observed to drop to those found in lean (wild-type) levels and was inversely correlated to leptin levels. In the mice receiving gene therapy, the low insulin levels were sustained for at

least one week whereas in the recombinant leptin-treated mice, insulin levels increased to pre-treatment levels within 24 hours post injection.

Glucose: The levels of glucose in plasma was also
5 measured in mice receiving recombinant leptin and those receiving the gene therapy treatment. In both groups, the glucose levels dropped within 6-9 days post treatment. The recombinant protein-treated mice did not achieve levels comparable to those found in lean, wild-type mice, and only sustained the lower level for less than one week. On the
10 other hand, the mice which received the gene therapy had reductions in glucose levels to that of wild type lean mice, and they sustained this reduced level for at least two weeks. This is illustrated in Figure 8.

The following non-limiting Examples are presented to better illustrate the invention.

15

EXAMPLE 1

Cloning and expression of leptin

Two PCR cDNA amplification fragments were obtained
20 from Jefferson University (generated by cloning both variants from a Clontech phage human hypothalamic library): one coding for the human leptin and one for the human leptin variant with glutamine, (Zhang *et al.*, 1994, *Nature* 372:425; Considine *et al.*, 1995 *J. Clin. Invest.* 95:2986). Both PCR fragments were amplified for cloning purposes.

25 Two primers were designed and ordered from GIBCO BRL Custom Primers: Forward primer: ATG CAT TGG GGA ACC CTG TG

Reverse primer: TCA GCA CCC AGG GCT GAG GT

The primers were used to re-amplify the cDNA as follows:
2 µl each primer (0.3 µg/µl stock), 2 µl dNTP (10 µM, Pharmacia), 10
30 µl 10 X PCR Buffer (Buffer 2 from Expand Long Template PCR System Kit, Boehringer Mannheim), 2 µl Taq polymerase (Perkin Elmer), 3 µl template DNA and 18 µl water. PCR cycling conditions were as follows: Mixture was incubated at 94°C initially (without the addition of the Taq enzyme) for 1-2 minute, Taq was then added to each
35 tube and the cycling program was initiated. 20 cycles of 94°C for 30

seconds, 45°C for 45 seconds and 72°C for 1 minute. At the end of the 20 rounds of amplification the samples were incubated at 72°C for 7 minutes. The expected fragment size in each case (human leptin - hOb, and human leptin with glutamine-hObGLN) was 501 and 504,

5 respectively. The PCR amplified fragments were cloned into pCR-Script SK(+) plasmid (Stratagene) and several selected bacterial colonies were grown, plasmids extracted and sequenced to verify correct sequence of both cloned.

10 Inserts were then used for generating recombinant adenoviral shuttle vectors. The adenoviral vectors used in this study are essentially the same as those described in Morsey et al 1993 *J. Clin. Invest.* 92: 1580-86, which is hereby incorporated by reference, except for the leptin gene insert. The pdeIE1sp1CMV-BGHpA adenoviral shuttle vector, obtained from Baylor College of Medicine was used for
15 the cloning of the two inserts (hOb and hObGLN). Similarly mOb cDNA (Zhang *et al.*, 1994 *Nature* 372:425) was inserted into pdeIE1sp1CMV-BGHpA. All three shuttles (pdeIE1sp1CMV-mOb-BGHpA, pdeIE1sp1CMV-hOb-BGHpA and pdeIE1sp1CMV-hObGLN-BGHpA) were tested for leptin expression by western blot analysis.
20

EXAMPLE 2

The three shuttle vectors from the previous example are used in rescue replication of the deficient E1 deleted adenoviral vectors.
25 293 cells, commercially available from Microbix, passage 27-30 were set up one day ahead of transfection in 60mm dishes, and were about 70-80% confluent at the time of use.

Plates were made containing one of the shuttle plasmids and pJM17; pFG140 (purchased from Microbix Biosystems Inc.) was used as
30 a positive control for the efficiency of transfection. Plaques were identified, and plugged out of the agarose overlay using a sterile glass Pasteur pipette. Each plugged plaque was resuspended in 100-500 µl of PBS (with calcium and magnesium) in 10% glycerol, frozen at -80°C and thawed (1-3 times). The thawed plaque was then used to infect a
35 90% confluent 6 cm plate of 293 cells to expand the isolated virus. 5-8

days post infection, cytopathic effects (cpe) were apparent on the cells (cells rounded up and started to detach and float in media). Cells were collected by scraping and tested for leptin expression by western analysis and for DNA restriction pattern by Hind III digestion of extracted DNA and ethidium bromide stained gel analysis. One of the positive plaques identified based on leptin secretion and correct DNA restriction pattern was selected and used for a second plaque purification followed by a similar procedure of expansion and analysis. After the second plaque purification, the virus was propagated on a large scale. Cesium banding and titration was used to purify and quantitate.

The resulting titered viral stocks (Ad-HCMV-mOb-BGH^{PA}, Ad-HCMV-hOb-BGH^{PA} and Ad-HCMV-hOb GLN-BGH^{PA}) were stored at -80°C until use.

EXAMPLE 3

Transgenic mice

Baseline determinations Three groups of mice were used: *ob/ob*, *dh/dh*, and lean (wild type, controls). All groups of mice were fed milled rodent chow (5008) starting from day of arrival or day after arrival. Food consumption was also measured. After approximately 4 days on milled chow, the mice were weighed and bled for determination of plasma levels of glucose and insulin. Injections were started 8 days after the initiation of base line measurements but before injections, mice were weighed and blood samples were obtained from all study mice for determination of plasma glucose and insulin. Leptin level in plasma were also measured.

Mice were housed 5 per cage and fed milled Purina Chow 5008 in feed cups with lids. 24 hour food consumption was measured at the same time each day. Only after food consumption was equilibrated to a fairly constant level, usually 20-25 grams chow/5 mice-day, was virus injected.

On the day of injection but before injection, food consumption, body weight, and a baseline blood sample were taken in the morning from a snipped end of tail. Blood was collected into heparinized capillary tube (total volume approximately 70-100 μ l).

- 5 Hematocrit was measured, and plasma was collected.

Mice were injected as follows:

- A. *ob/ob* mouse groups: iv injections, 5 mice/group

Group 1 received 2.75×10^8 / gm wt of AdHCMV-hob-BGH^{PA} (in 500 μ l dialysis buffer) in the tail vein.

- 10 Group 2 received 2.75×10^8 / gm wt of AdHCMV- β gal reporter (in 500 μ l dialysis buffer) in tail vein.

Group 3 received 500 μ l dialysis buffer in tail vein.

Group 4 received 1 mg/kg wt active leptin daily IP injections for 5 days.

15

- B. *db/db* mouse groups: iv injections, 5 mice/group

Group 1 received 2.75×10^8 / gm wt of AdHCMV-hob-BGH^{PA} (in 500 μ l dialysis buffer) in the tail vein.

- 20 Group 2 received 2.75×10^8 / gm wt of AdHCMV- β gal reporter (in 500 μ l dialysis buffer) in tail vein.

Group 3 received 1 mg/kg wt active leptin daily IP injections for 5 days.

- 25 C. Lean control mouse group: one cage of 5 mice as measure of lean parameters

No injections.

EXAMPLE 4

- 30 Leptin receptor

Adenovirus vectors are made similarly to those described in Examples 2-3, except that the leptin receptor gene replaces the leptin gene. Mice which are *db/db* are used in place of the *ob/ob* mice. Results for the *db/db* mice are similar to those observed with the *ob/ob*

mice reported herein. After injection, glucose levels fall, insulin levels fall and the mice loose weight. No effect is observed in control mice and in *ob/ob* mice injected with vector carrying a leptin receptor gene.

5 DETAILED DESCRIPTION OF THE INVENTION
Not Applicable

WHAT IS CLAIMED:


1. A method of treating obesity, lowering serum glucose levels or lowering serum insulin levels in a mammal in need of such therapy comprising delivering an obesity regulating gene to the mammal; wherein transcription and translation of the gene occurs *in vivo*.
2. A method of treating obesity, lowering serum glucose levels or lowering serum insulin levels in a mammal in need of such therapy comprising delivering a gene encoding a leptin to the mammal; wherein transcription and translation of the gene encoding leptin occurs *in vivo*.
3. A method according to Claim 2 wherein the heterologous gene encoding a leptin is delivered in a vector.
4. A method according to Claim 3 wherein the vector is an adenovirus.
5. A method according to Claim 4 wherein the adenovirus is expressed in liver.
6. A method according to Claim 1 wherein the mammal is a human.
7. A method of treating obesity which is, at least in part, due to an insufficient amount of leptin receptors produced by a mammal comprising:
 - a) transfecting the mammal with a viral vector comprising a gene encoding a leptin receptor; wherein said vector further comprises at least one element regulating its expression in a mammalian tissue; and

- b) allowing sufficient time to pass for transcription and translation of the leptin receptor gene.

- 5 8. A method according to Claim 7 wherein the vector is
a viral vector.
9. A method according to Claim 8 wherein the vector is
an adenovirus.
- 10 10. A method according to Claim 9 wherein the
adenovirus is expressed in liver.
11. A method according to Claim 10 wherein the
15 mammal is a human.
12. A vector comprising a gene encoding a leptin
receptor; wherein said vector further comprises at least one element
regulating its expression in a mammalian tissue.
- 20 13. A method according to Claim 7 wherein the vector is
an adenovirus.

FIG. 1


**Adeno-mediated human leptin delivery and expression in ob/ob mice
Phenotypic Correction 10 Days Post Treatment**



ob/ob treated with a single IV dose
(2.75×10^8 pfu) of Ad-HCMV-hOb

Untreated ob/ob or treated
with control virus Ad-HCMV- β gal

2/8



SUBSTITUTE SHEET (RULE 26)

3/8




FIG.3

SUBSTITUTE SHEET (RULE 26)

4/8




FIG.4

SUBSTITUTE SHEET (RULE 26)

5/8





FIG.5


SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

FIG. 7

Plasma levels of insulin in ob/ob treated mice



◆ Human leptin in ob/ob treated with 1ug/gm recombinant protein daily for 5 days


■ Human leptin in ob/ob treated with a single injection of 2.75x10⁸ pfu of viral vector

◆ Lean Insulin levels

■ Insulin in adeno-treated ob/ob

◆ Insulin in recom. leptin treated ob/ob

8/8



IP INJECTION OF RECOMBINANT
HUMAN LEPTIN (1ug/gm BODY WT)

FIG. 8

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/12131

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 48/00; C12N 15/12, 15/86

US CL : 435/320.1; 424/93.2; 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1; 424/93.2; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS; DIALOG DATABASES: BIOSIS, MEDLINE, CA SEARCH, WORLD PATENT INDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/05309 A2 (THE ROCKEFELLER UNIVERSITY) 22 February 1996, see entire document.	1-6
X	FLETCHER, F.A. et al. Replacement Gene Therapy Phenotypically Corrects the Fat Deposition Defect in ob/ob Mice. Blood. 15 November 1995, page 241a, abstract 951, see entire abstract..	1-3 6
Y		
X,P	MUZZIN, P. et al. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc. Natl. Acad. Sci. USA. December 1996, Vol. 93, pages 14804-14808, see entire document..	1-5

<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.	<input type="checkbox"/> See patent family annex.										
<p>* Special categories of cited documents:</p> <table><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*E* earlier document published on or after the international filing date</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td>*Z* document member of the same patent family</td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>		*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*O* document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family	*P* document published prior to the international filing date but later than the priority date claimed	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention										
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone										
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art										
O document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family										
P document published prior to the international filing date but later than the priority date claimed											
Date of the actual completion of the international search 02 SEPTEMBER 1997	Date of mailing of the international search report 31 OCT 1997										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JOHNNY F. RAILEY II, PH.D. Telephone No. (703) 308-0196										

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/12131

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	CHEN, G. et al. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy. Proc. Natl. Acad. Sci. USA. December 1996, Vol. 93, pages 14795-14799, see entire document.	1-5
X,P	WO 96/35787 A1 (CHIRON CORPORATION) 14 November 1996, see entire document.	1-5
X,P	WO 97/19952 (MILLENNIUM PHARMACEUTICALS, INC.) 05 June 1997, see entire document, especially pages 43 and 45.	12
Y,P		1,7-11,13